Our Science

IsomAb is taking a completely novel approach to identifying, evaluating and developing isoform specific antibodies to treat cardiovascular diseases where patients currently have limited or no treatment options.

IsomAb has invented ISM-001, which specifically inhibits the VEGF-A165b isoform of Vascular Endothelial Growth Factor-A (VEGF-A). This key protein is involved in the regulation of angiogenesis – the process of forming new blood vessels – particularly in atherosclerotic conditions.

Based on 20 years of discovery research by IsomAb’s two founders, the evidence strongly supports that reducing levels of VEGF-A165b can promote new blood vessel formation, helping to restore blood flow to tissues.

When VEGF-A165b levels are high, the normal angiogenic signalling process that promotes blood vessel growth is inhibited, even in the presence of VEGF-A165a. Therefore, blocking the activity of VEGF-A165b through targeted therapies could remove this ‘brake,’ allowing VEGF-A165a to promote angiogenesis and improve blood supply in ischaemic tissues.